vs
Side-by-side financial comparison of ASTRAZENECA PLC (AZN) and Pfizer (PFE). Click either name above to swap in a different company.
ASTRAZENECA PLC is the larger business by last-quarter revenue ($14.5B vs $14.5B, roughly 1.0× Pfizer). Pfizer runs the higher net margin — 18.6% vs 16.9%, a 1.7% gap on every dollar of revenue. On growth, ASTRAZENECA PLC posted the faster year-over-year revenue change (11.7% vs 5.0%).
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer (1824–1906) and Charles F. Erhart (1821–1891), Pfizer is one of the oldest pharmaceutical companies in North America.
AZN vs PFE — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $14.5B | $14.5B |
| Net Profit | $2.4B | $2.7B |
| Gross Margin | 82.9% | — |
| Operating Margin | 24.3% | — |
| Net Margin | 16.9% | 18.6% |
| Revenue YoY | 11.7% | 5.0% |
| Net Profit YoY | 27.0% | — |
| EPS (diluted) | $1.57 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $14.5B | ||
| Q4 25 | — | $17.6B | ||
| Q3 25 | — | $16.7B | ||
| Q2 25 | $14.5B | $14.7B | ||
| Q1 25 | — | $13.7B | ||
| Q4 24 | — | $17.8B | ||
| Q3 24 | — | $17.7B | ||
| Q2 24 | $12.9B | $13.3B |
| Q1 26 | — | $2.7B | ||
| Q4 25 | — | $-1.6B | ||
| Q3 25 | — | $3.5B | ||
| Q2 25 | $2.4B | $2.9B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $410.0M | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | $1.9B | $41.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 70.0% | ||
| Q3 25 | — | 74.9% | ||
| Q2 25 | 82.9% | 74.2% | ||
| Q1 25 | — | 79.3% | ||
| Q4 24 | — | 66.7% | ||
| Q3 24 | — | 70.3% | ||
| Q2 24 | 83.1% | 75.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | -9.4% | ||
| Q3 25 | — | 20.0% | ||
| Q2 25 | 24.3% | 20.8% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | — | 26.6% | ||
| Q2 24 | 21.2% | -0.8% |
| Q1 26 | — | 18.6% | ||
| Q4 25 | — | -9.4% | ||
| Q3 25 | — | 21.3% | ||
| Q2 25 | 16.9% | 19.9% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 25.2% | ||
| Q2 24 | 14.9% | 0.3% |
| Q1 26 | — | $0.47 | ||
| Q4 25 | — | $-0.29 | ||
| Q3 25 | — | $0.62 | ||
| Q2 25 | $1.57 | $0.51 | ||
| Q1 25 | — | $0.52 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $0.78 | ||
| Q2 24 | $1.24 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.8B | — |
| Total Assets | $112.4B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $7.1B | $1.6B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | $6.9B | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | $86.5B | ||
| Q3 25 | — | $92.8B | ||
| Q2 25 | $44.8B | $88.7B | ||
| Q1 25 | — | $90.3B | ||
| Q4 24 | — | $88.2B | ||
| Q3 24 | — | $92.3B | ||
| Q2 24 | $39.6B | $87.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | $208.2B | ||
| Q3 25 | — | $208.7B | ||
| Q2 25 | $112.4B | $206.1B | ||
| Q1 25 | — | $208.0B | ||
| Q4 24 | — | $213.4B | ||
| Q3 24 | — | $219.5B | ||
| Q2 24 | $104.3B | $216.2B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZN
Segment breakdown not available.
PFE
| Product revenues | $11.7B | 81% |
| Alliance revenues | $2.3B | 16% |
| Royalty revenues | $396.0M | 3% |
